{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Chemomab Therapeutics Ltd. "},"Symbol":{"label":"Symbol","value":"CMMB"},"Address":{"label":"Address","value":"KIRYAT ATIDIM,BUILDING 7, TEL AVIV, 6158002, Israel"},"Phone":{"label":"Phone","value":"+972 773310156"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"Middle East"},"CompanyDescription":{"label":"Company Description","value":"Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet need. The company's lead candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions."},"CompanyUrl":{"label":"Company Url","value":"https://www.chemomab.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Adi Mor","title":"Chief Executive Officer & Director"},{"name":"Ilan Vaknin","title":"Vice President-Research & Development"},{"name":"Jack Lawler","title":"VP-Global Clinical Development Operations"},{"name":"Matthew B. Frankel","title":"Chief Medical Officer & VP-Drug Development"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}